Profile data is unavailable for this security.
About the company
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-10.71m
- Incorporated2018
- Employees9.00
- LocationShuttle Pharmaceuticals Holdings Inc401 Professional Drive, Suite 260GAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 403-4212
- Fax+1 (845) 818-3588
- Websitehttps://shuttlepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hcw Biologics Inc | 422.03k | -22.21m | 2.68m | 36.00 | -- | -- | -- | 6.34 | -13.96 | -13.96 | 0.2716 | -0.8038 | 0.0162 | -- | 1.24 | 11,723.06 | -46.35 | -53.89 | -- | -66.10 | 20.00 | -- | -2,855.77 | -545.79 | -- | -42.26 | 1.45 | -- | -9.68 | -- | -20.12 | -- | -29.10 | -- |
| Artelo Biosciences Inc | 0.00 | -12.49m | 2.68m | 5.00 | -- | -- | -- | -- | -20.88 | -20.88 | 0.00 | -0.407 | 0.00 | -- | -- | 0.00 | -219.08 | -- | -427.33 | -- | -- | -- | -- | -- | -- | -91.40 | 3.62 | -- | -- | -- | -5.78 | -- | -- | -- |
| Oragenics Inc | 0.00 | -10.90m | 2.76m | 3.00 | -- | 0.2783 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 4.80m | -8.21m | 2.78m | 13.00 | -- | 0.2224 | -- | 0.5786 | -7.21 | -7.21 | 2.65 | 4.45 | 0.4028 | 3.01 | 15.28 | -- | -68.93 | -87.37 | -78.82 | -107.49 | 33.69 | -- | -171.13 | -356.16 | 6.37 | -27.94 | 0.00 | -- | 7.50 | -- | -6.34 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 2.90m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 2.93m | 5.00 | -- | 0.1333 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -10.71m | 3.00m | 9.00 | -- | 0.9926 | -- | -- | -25.86 | -25.86 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -507.78 | -- | -3,614.50 | -- | -- | -- | -- | -- | -- | -- | 0.2305 | -- | -- | -- | -38.71 | -- | -- | -- |
| Psyence Biomedical Ltd | -100.00bn | -100.00bn | 3.03m | 12.00 | -- | 0.012 | -- | -- | -- | -- | -- | 247.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 101.98 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -63.41m | 3.13m | 1.00 | -- | 0.2171 | -- | -- | -45.47 | -45.47 | 0.00 | 1.08 | 0.00 | -- | -- | 0.00 | -702.98 | -- | -1,223.40 | -- | -- | -- | -- | -- | -- | -56.99 | 0.0422 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -8.05m | 3.17m | 5.00 | -- | 0.6032 | -- | -- | -23.22 | -23.22 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -130.16 | -205.76 | -155.01 | -274.10 | -- | -- | -- | -- | -- | -27.38 | 0.00 | -- | -- | -- | -88.48 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -376.18k | 3.25m | 0.00 | -- | 12.93 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
| Vaccinex Inc | 601.00k | -18.63m | 3.35m | 23.00 | -- | -- | -- | 5.57 | -9.91 | -9.91 | 0.2864 | -0.9295 | 0.193 | -- | 0.6682 | 26,130.44 | -598.49 | -299.11 | -- | -- | -- | -- | -3,100.50 | -3,700.14 | -- | -149.88 | -- | -- | 5.44 | 2.82 | 7.98 | -- | -22.36 | -- |
| ABPRO Holdings Inc | 0.00 | -22.04m | 3.45m | 6.00 | -- | -- | -- | -- | -24.37 | -24.37 | 0.00 | -6.04 | 0.00 | -- | -- | 0.00 | -467.23 | -- | -- | -- | -- | -- | -- | -- | -- | -4.82 | -- | -- | 50.00 | -- | -48.72 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Connective Capital Management LLCas of 30 Sep 2025 | 100.54k | 21.79% |
| DRW Securities LLCas of 30 Sep 2025 | 42.83k | 9.29% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 9.25k | 2.00% |
| UBS Securities LLCas of 31 Dec 2025 | 2.70k | 0.59% |
| Tower Research Capital LLCas of 30 Sep 2025 | 1.02k | 0.22% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025 | 27.00 | 0.01% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 8.00 | 0.00% |
| Desjardins Securities, Inc.as of 30 Sep 2025 | 2.00 | 0.00% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Sep 2025 | 0.00 | 0.00% |
